Natera, Inc. $NTRA Shares Sold by Millennium Management LLC

Key Points

• Millennium Management LLC has reduced its stake in Natera, Inc. by 33.6%, selling 129,561 shares and now holds approximately 0.19% of the company's stock, valued at $36.16 million.
• Natera reported a quarterly revenue of $546.60 million, significantly exceeding the consensus estimate of $476.84 million, despite posting a loss of ($0.74) earnings per share, which missed expectations.
• Several analysts have reiterated a "buy" or "overweight" rating for Natera, with target prices up to $268.00, indicating strong confidence in the stock despite its recent earnings miss.

Millennium Management LLC decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 33.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 255,683 shares of the medical research company's stock after selling 129,561 shares during the quarter. Millennium Management LLC owned about 0.19% of Natera worth $36,156,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. LRI Investments LLC acquired a new position in Natera during the fourth quarter worth about $29,000. Bank of Jackson Hole Trust acquired a new position in Natera during the first quarter worth about $29,000. Rakuten Securities Inc. boosted its position in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new position in Natera during the first quarter worth about $32,000. Finally, TCTC Holdings LLC boosted its position in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ NTRA traded down $5.30 during mid-day trading on Friday, reaching $168.51. 853,091 shares of the company's stock were exchanged, compared to its average volume of 978,479. The company's 50-day moving average is $155.18 and its 200-day moving average is $154.18. The firm has a market capitalization of $23.13 billion, a price-to-earnings ratio of -88.23 and a beta of 1.68. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The business's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 4,299 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This represents a 34.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,423 shares of company stock worth $8,459,656. 5.63% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on NTRA. Piper Sandler restated an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Barclays restated an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Finally, Stephens reiterated an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.